Apogee Therapeutics Inc. [APGE] stock prices are up 5.33% to $53.34 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The APGE shares have gain 5.37% over the last week, with a monthly amount glided 6.59%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Apogee Therapeutics Inc. [NASDAQ: APGE] stock has seen the most recent analyst activity on May 10, 2024, when BofA Securities initiated its Buy rating and assigned the stock a price target of $80. Previously, BTIG Research started tracking the stock with Buy rating on December 20, 2023, and set its price target to $43. On August 08, 2023, Wedbush initiated with a Outperform rating and assigned a price target of $40 on the stock. TD Cowen started tracking the stock assigning a Outperform rating. Stifel initiated its recommendation with a Buy and recommended $34 as its price target on August 08, 2023. Jefferies started tracking with a Buy rating for this stock on August 08, 2023, and assigned it a price target of $29. In a note dated August 08, 2023, Guggenheim initiated an Buy rating and provided a target price of $29 on this stock.
The stock price of Apogee Therapeutics Inc. [APGE] has been fluctuating between $14.19 and $72.29 over the past year. Currently, Wall Street analysts expect the stock to reach $95 within the next 12 months. Apogee Therapeutics Inc. [NASDAQ: APGE] shares were valued at $53.34 at the most recent close of the market. An investor can expect a potential return of 78.1% based on the average APGE price forecast.
Analyzing the APGE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -0.19 and Total Capital is -0.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 50.80 points at the first support level, and at 48.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 54.82, and for the 2nd resistance point, it is at 56.30.
Ratios To Look Out For
It’s worth pointing out that Apogee Therapeutics Inc. [NASDAQ:APGE]’s Current Ratio is 27.70. Further, the Quick Ratio stands at 27.70, while the Cash Ratio is 12.48.
Transactions by insiders
Recent insider trading involved Dambkowski Carl, Chief Medical Officer, that happened on Sep 04 ’24 when 6665.0 shares were sold. Chief Executive Officer, HENDERSON MICHAEL THOMAS completed a deal on Sep 04 ’24 to sell 40000.0 shares. Meanwhile, Officer HENDERSON MICHAEL THOMAS bought 40000.0 shares on Sep 04 ’24.
